SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (21457)5/27/1998 10:18:00 PM
From: Cacaito  Read Replies (2) | Respond to of 32384
 
Orphan Drug Status gives 7 years of market exclusivity for the product, not for the disease treatment is intended to.

Paxene and Taxol are both brands of Paclitaxel. Therefore the first one to get the orphan drug status gets the exclusivity.

This is not exclusivity to treat a disease (nobody has patented the intent to treat a disease yet).

Panretin is a completely different compound, no relation to paclitaxel. Therefore no threat of exclusion from the market.

Panretin has the additional protection of a much safer side effects profile vs paclitaxel.

The only thing to be worry is from poor data, and panretin data is very, very strong in both the clinical and statistical aspects.



To: Flagrante Delictu who wrote (21457)6/1/1998 12:21:00 PM
From: Henry Niman  Respond to of 32384
 
Bernie, The Orphan Drug act prevents licensing of a similar drug for the same condition. I believe that NPRO's drug is another version of Taxol. Of course Panretin oral is not related and would not be impacted for KS or other indications.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News